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Choosing drugs for secondary prevention after myocardial infarction: a pragmatic approach Historical perspective Early mortality from acute myocardial infarction may be reduced by thrombolytic agents'-4 and late mortality following hospital discharge by the use of several oral agents (table 1).5 These drugs also reduce morbidity from reinfarction and heart failure. The first drugs shown in large scale clinical trials over a decade ago to be beneficial in the recovery period following acute myocardial infarction were oral anticoagulants.6 However, their widespread application was limited by concerns about their safety and by the need to monitor carefully the level of anticoagulation.
Historically, 13-adrenoceptor blockers7-9 were the next drugs to be shown to be of benefit but again, their use was hindered by concerns over safety in patients with heart failure and their side-effect profile. As a consequence, they are not used as often as they could be. By comparison, low-dose aspirin has been shown to be effective and is well tolerated.5 Just recently, two major trials'0"' have shown the benefit of angiotensin-converting enzyme (ACE) inhibitors to patients with covert and especially overt heart failure following acute myocardial infarction. Drugs which lower cholesterol levels also appear to reduce reinfarction and mortality. ' If a combination of drugs were to be used then it would be reasonable to chose another drug which exerted its effect in a different way. Certain lipid-soluble P-adrenoceptor blocking drugs have proven benefits in patients after myocardial infarction and although contra-indicated in patients with overt heart failure, are often tolerated well by patients with left ventricular damage who are symptomless.'0 Indeed, patients with mild heart failure appeared of benefit most from the treatment.9 Echocardiographic data'5'16 show that ACE inhibitors reduce left ventricular dilatation which occurs progressively following anterior myocardial infarction, and this is thought to be a precursor of left ventricular failure. In patients with overt heart failure the benefits of ACE inhibitors are now established. They improve symptoms, slow the rate of left ventricular deterioration, and improve short-term mortality. '7 In patients with asthma and no heart failure in whom Padrenoceptor blockers are contra-indicated, verapamil'3 could be used.
Oral anticoagulants are indicated for patients with atrial fibrillation, left ventricular aneurysms, and patients with severe congestive cardiac failure. Recent evidence suggests that lowering serum cholesterol by simvastatin in patients with previous infarction or angina with serum cholesterol in the range 5.5-8.0 mmol/l who were already on a lipid-lowering diet also reduces subsequent cardiovascular events and total mortality. The algorithm (figure) provides a decision route for the choice of drug(s) for secondary prevention.
Conclusion
A simple approach to secondary prevention is therefore to give all patients aspirin and other drugs using clinical 
